Composition and method for treating carcinoma

A method for treating prostate cancer in a patient who has a PSA level above about 5, the method comprising measuring the PSA level in the blood of the patient, administering Rhodamine-123 to the patient in an amount sufficient to effect in vivo destruction of prostate cancer cells, and thereafter measuring the patient's PSA level to confirm the destruction of prostate cancer cells in the patient.

A solution which treats carcinoma in a patient comprising ethyl alcohol and an effective amount of Rhodamine-123 dissolved in water.

A stock solution for preparing an administration solution which treats carcinoma in a patient, the stock solution comprising Rhodamine-123 dissolved in ethyl alcohol.

A method for treating prostate cancer in a patient who has a PSA level above about 5, the method comprising oral administration of Rhodamine-123 in a pill which releases the Rhodamine-123 for absorption by the patient, and in an amount sufficient to effect in vivo destruction of prostate cancer cells in the patient, measuring the patient's PSA level after treatment, and thereafter administering Rhodamine-123 to the patient at a rate sufficient to substantially decrease the patient's PSA level.

A method for treating prostate carcinoma in a patient with prostate carcinoma, the method comprising treating the patient by dissolving Rhodamine-123 in a solvent which includes ethyl alcohol to form a stock solution, diluting the stock solution with water to form a treatment solution which includes Rhodamine-123, water and ethyl alcohol, and administering the treatment solution to the patient in an amount sufficient to effect in vivo destruction of prostate carcinoma cells.

A method for treating prostate cancer in a patient who has a PSA level above about 5, the method comprising measuring the prostate specific acid phosphatase level in the blood of the patient, administering Rhodamine-123 to the patient in an amount sufficient to effect in vivo destruction of prostate cancer cells, and thereafter measuring the patient's prostate specific acid phosphatase level to confirm the destruction of prostate cancer cells in the patient.

A method for treating prostate cancer in a patient comprising dissolving Rhodamine-123 in a solvent which includes ethyl alcohol to form a stock solution, diluting the stock with water to form a treatment solution which includes Rhodamine-123, water and ethyl alcohol, administering the treatment solution to the patient in an amount sufficient to effect in vivo destruction of prostate cancer cells, measuring the patient's prostate specific acid phosphatase level before and after treatment, and administering sufficient Rhodamine-123 to substantially decrease the level of prostate specific acid phosphatase in the blood of the patient.

A method for treating carcinoma in a patient comprising intravenous administration of a solution of Rhodamine-123 in ethyl alcohol and water in an amount sufficient to effect in vivo destruction of carcinoma cells.

A method for treating carcinoma in a patient comprising administering Rhodamine-123 to the patient in an amount sufficient to effect in vivo destruction of carcinoma cells.

A method for treating prostate cancer in a patient comprising administering Rhodamine-123 to the patient in an amount sufficient to effect in vivo destruction of prostate cancer cells.